DOSSIER · 13F-HR · Q2 2026

Decheng Capital LLC

$732M in tracked AUM across 14 positions as of Q2 2026.

DC
CIK 0002010850 · last filed Jun 30, 2026
Total AUM
$732M
as of Q2 2026
Holdings
14
positions
Whale Score
75
75
strong
Activity
no data
changes this Q
AI Analysis · Q2 2026

Portfolio Overview

Decheng Capital LLC’s 13F filing for the period ending September 30, 2025, reveals a concentrated portfolio focused on the biotechnology and healthcare sectors. The firm manages a total portfolio value of approximately $255.92 million across 16 holdings. This represents a significant reduction in capital deployment, with the total portfolio value decreasing by 35.4% from the previous quarter's $395.97 million.

The portfolio is characterized by high conviction, with the t...

Key Holdings

The portfolio is heavily dominated by mid-to-large cap biotechnology positions, with a distinct skew toward clinical-stage companies.

Analysis generated by 13F Insight from SEC Form 13F filing data · Q2 2026. Methodology

Quarter at a glance — Q2 2026

Position-change comparison pending.

No quarter-over-quarter changes available.

Top 10 holdings

By portfolio weight as of Q2 2026.

#HoldingValueSharesWeight
01
CGON
CG ONCOLOGY INC
$453M6.4M61.9%
02
NUVB
Nuvation Bio Inc.
$147M26.0M20.1%
03
AARD
AARDVARK THERAPEUTICS INC
$23M3.9M3.1%
04
ACRS
Aclaris Therapeutics, Inc.
$21M4.0M2.9%
05
UPB
Upstream Bio Inc.
$19M2.7M2.6%
06
RCUS
Arcus Biosciences, Inc
$14M465K2.0%
07
EQ
Equillium Inc.
$14M4.4M1.9%
08
RVMD
REVOLUTION MEDICINES INC(NSM)
$10M53K1.3%
09
55083R104
Lyell Immunopharma, Inc.
$10M692K1.3%
10
G10830100
BeyondSpring Inc.
$7M3.8M0.9%

Filing history

2026Q2Jun 30
$732M 10.7%
14 positionsView →
2026Q1Mar 31
$661M 11.0%
14 positionsView →
2025Q4Dec 31
$743M 190.5%
19 positionsView →
2025Q3Sep 30
$256M 35.4%
16 positionsView →
2025Q2Jun 30
$396M 152.7%
25 positionsLocked
2025Q1Mar 31
$157M 66.4%
20 positionsLocked
2024Q4Dec 31
$466M 10.4%
28 positionsLocked
2024Q3Sep 30
$422M 29.4%
26 positionsLocked
2024Q2Jun 30
$326M 56.2%
24 positionsLocked
2024Q1Mar 31
$746M 108.3%
22 positionsLocked
2023Q4Dec 31
$358M
24 positionsLocked